You are here: Industry Insights > Dr. Reddy

News List

Dr. Reddy's Laboratories Announces the Launch of Venlafaxine ER Tablets in the U.S. Market AmericanPharmaceuticalReview
December 13, 2021
Dr. Reddy’s Laboratories Ltd. announced the launch of Venlafaxine ER Tablets which is therapeutically equivalent to Venlafaxine Extended-Release Tablets, 150 mg and 225 mg, of Osmotica Pharmaceutical US LLC approved by the U.S. Food and Drug ...
Dr. Reddy's Launches Vigabatrin Powder for Oral Solution, USP in the U.S. Market americanpharmaceuticalreview
August 22, 2019
Dr. Reddy’s Laboratories has announced the launch of Vigabatrin Powder for Oral Solution, USP in 500 mg per packet, a therapeutic equivalent generic version of Sabril® (vigabatrin) Powder for Oral Solution ...
Dr. Reddy's Laboratories Launches Versavo® in India americanpharmaceuticalreview
August 20, 2019
Dr. Reddy’s Laboratories Ltd. has launched Versavo® (bevacizumab), a biosimilar of Roche’s Avastin® in India, indicated for the treatment of several types of cancers (metastatic colorectal cancer, non-squamous non-small cell lung cancer
Dr. Reddy's Copaxone, NuvaRing generics derailed by FDA fiercepharma
August 18, 2019
Dr. Reddy’s, which has been dealing with repeated manufacturing setbacks from the FDA, is now facing a new regulatory challenge.
Dr. Reddy's Copaxone, NuvaRing generics derailed by FDA fiercepharma
August 15, 2019
Dr. Reddy’s, which has been dealing with repeated manufacturing setbacks from the FDA, is now facing a new regulatory challenge.
Another day, another Form 483 for a Dr. Reddy's plant fiercepharma
August 04, 2019
FDA inspectors keep hitting replay for Dr. Reddy’s Laboratories plants as they make their way through its manufacturing sites.
Dr. Reddy's Announces Launch of Carboprost Tromethamine Injection americanpharmaceuticalreview
July 04, 2019
Dr. Reddy’s announced the launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose Vial, a therapeutic equivalent generic version of Hemabate® injection, 250 mcg/mL, approved by the U.S. Food and Drug Administration (FDA).
Dr. Reddy's announces positive topline results from Phase 2b biospectrumasia
June 10, 2019
PPC-06 is an extended release formulation of a fumaric acid ester (FAE), in-licensed from Xenoport, Inc. for further development to treat moderate to severe plaque psoriasis.
Dr. Reddy's solid dose plant pinched by FDA for missteps fiercepharma
March 03, 2019
The FDA keeps rolling through the Indian manufacturing plants of Dr. Reddy’s Laboratories, and the Form 483s keep falling out.
Dr. Reddy's racks up more repeat violations at Bachupally formulations plant fiercepharma
February 24, 2019
Dr. Reddy’s, which has been struggling to bring a number of its key plants up to FDA standards, has been unable to learn from past mistakes, including at its formulations plant in Bachupally.

Previous page 1 2 Next page